Vor Biopharma, following significant workforce reductions and strategic review, has pivoted from oncology to autoimmune disease therapies by licensing telitacicept—a dual-target fusion protein approved in China for myasthenia gravis, lupus, and rheumatoid arthritis—from RemeGen. The company appointed former MorphoSys CEO Jean-Paul Kress and raised $175 million via a private equity placement. The in-licensed drug is undergoing Phase 3 trials globally, positioning Vor as a growing player in the autoimmune therapeutic market.